Employees: 258
Size Geron (GERN) is a United States Health Care company (Biotechnology) with a market value of $638M, the 2516th largest of 3,085 United States companies the cockpit tracks. Shares closed at $0.99 on 18 Nov 2026.
Performance Over six months the shares fell 21.4%, against -13.8% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 19 in its peer set.
Growth Revenue grew 18.6% over the last twelve months (peer median +18.1%); the operating margin is -8.2% (peer median -178.2%).
Valuation It trades at 17.4× forward earnings against a peer median of 23.2× (cheapest of 5).
Capital Return on invested capital runs 14.9 points below its cost of capital (7.4% WACC).
Short interest Short interest is 10.4% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $218M | $184M | $77.0M | $237,000 | $596,000 |
| Revenue growth | — | +139% | +32,387% | -60% | — |
| Gross profit | $206M | $179M | $75.7M | -$796,000 | -$272,000 |
| EBITDA | -$16.7M | -$50.3M | -$173M | -$193M | -$138M |
| Net income | -$50.1M | -$83.5M | -$175M | -$184M | -$142M |
| Free cash flow | -$91.2M | -$111M | -$219M | -$169M | -$128M |
| Capital expenditure | $629,000 | $49,000 | $680,000 | $830,000 | $431,000 |
| Total debt | $250M | $252M | $247M | $85.9M | $55.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GERN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.1% | -8.4% | 6th lowest of 21 |
| 6-month return | -21.4% | -13.8% | 9th lowest of 19 |
| Distance from 52-week high | -50.7% | -44.5% | 8th lowest of 21 |
| Revenue growth (TTM) | +18.6% | +18.1% | 8th highest of 16 |
| Operating margin | -8.2% | -178.2% | 5th highest of 17 |
| Forward P/E | 17.4× | 23.2× | cheapest of 5 |
| ROIC minus cost of capital | -14.9 pp | -15.2 pp | 5th highest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Geron GERN | United States | $638M | -21% | +19% | -8% | 17.4× | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 19.2× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | n/a | -8.9% | -1.3% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | n/a | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | n/a | 40.3% | +21.5% |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 24.0× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 22.3× | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | n/a | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | n/a | 44.8% | +14.7% |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | n/a | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | n/a | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 431.5× | 39.8% | +143.5% |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |